Ankyra Therapeutics, Inc

This early-stage study is testing whether a new drug called ANK-101, when combined with standard immunotherapy, can help control advanced non-small cell lung cancer. It will enroll 60 participants, including both patients who have already tried immunotherapy and those who haven't…

This is an early-stage safety study for a new drug called ANK-101, which is injected directly into tumors. It aims to find a safe dose for people with advanced solid cancers that have stopped responding to standard treatments. The study will test the drug alone in different types…